PortfoliosLab logo
EW vs. LLY
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Correlation

The correlation between EW and LLY is 0.47, which is considered to be moderate. This suggests that the two assets have some degree of positive relationship in their price movements. Moderate correlation can be acceptable for portfolio diversification, offering a balance between risk and potential returns.


Performance

EW vs. LLY - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Edwards Lifesciences Corporation (EW) and Eli Lilly and Company (LLY). The values are adjusted to include any dividend payments, if applicable.

Loading data...

Key characteristics

Sharpe Ratio

EW:

-0.33

LLY:

-0.03

Sortino Ratio

EW:

-0.02

LLY:

0.27

Omega Ratio

EW:

1.00

LLY:

1.04

Calmar Ratio

EW:

-0.18

LLY:

-0.00

Martin Ratio

EW:

-0.43

LLY:

-0.00

Ulcer Index

EW:

23.00%

LLY:

12.85%

Daily Std Dev

EW:

41.02%

LLY:

38.42%

Max Drawdown

EW:

-54.32%

LLY:

-68.27%

Current Drawdown

EW:

-40.31%

LLY:

-20.68%

Fundamentals

Market Cap

EW:

$45.10B

LLY:

$658.30B

EPS

EW:

$2.42

LLY:

$12.61

PE Ratio

EW:

31.77

LLY:

58.15

PEG Ratio

EW:

4.28

LLY:

1.10

PS Ratio

EW:

8.17

LLY:

13.43

PB Ratio

EW:

4.44

LLY:

40.75

Total Revenue (TTM)

EW:

$5.54B

LLY:

$49.00B

Gross Profit (TTM)

EW:

$4.39B

LLY:

$40.03B

EBITDA (TTM)

EW:

$1.77B

LLY:

$16.67B

Returns By Period

In the year-to-date period, EW achieves a 5.36% return, which is significantly higher than LLY's -1.52% return. Over the past 10 years, EW has underperformed LLY with an annualized return of 13.61%, while LLY has yielded a comparatively higher 28.65% annualized return.


EW

YTD

5.36%

1M

9.55%

6M

15.11%

1Y

-13.44%

5Y*

1.91%

10Y*

13.61%

LLY

YTD

-1.52%

1M

3.27%

6M

1.88%

1Y

-1.11%

5Y*

38.32%

10Y*

28.65%

*Annualized

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Risk-Adjusted Performance

EW vs. LLY — Risk-Adjusted Performance Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

EW
The Risk-Adjusted Performance Rank of EW is 3737
Overall Rank
The Sharpe Ratio Rank of EW is 3333
Sharpe Ratio Rank
The Sortino Ratio Rank of EW is 3535
Sortino Ratio Rank
The Omega Ratio Rank of EW is 3535
Omega Ratio Rank
The Calmar Ratio Rank of EW is 3939
Calmar Ratio Rank
The Martin Ratio Rank of EW is 4242
Martin Ratio Rank

LLY
The Risk-Adjusted Performance Rank of LLY is 4747
Overall Rank
The Sharpe Ratio Rank of LLY is 5050
Sharpe Ratio Rank
The Sortino Ratio Rank of LLY is 4343
Sortino Ratio Rank
The Omega Ratio Rank of LLY is 4343
Omega Ratio Rank
The Calmar Ratio Rank of LLY is 5151
Calmar Ratio Rank
The Martin Ratio Rank of LLY is 5050
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

EW vs. LLY - Risk-Adjusted Performance Comparison

This table presents a comparison of risk-adjusted performance metrics for Edwards Lifesciences Corporation (EW) and Eli Lilly and Company (LLY). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


The current EW Sharpe Ratio is -0.33, which is lower than the LLY Sharpe Ratio of -0.03. The chart below compares the historical Sharpe Ratios of EW and LLY, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.


Loading data...

Dividends

EW vs. LLY - Dividend Comparison

EW has not paid dividends to shareholders, while LLY's dividend yield for the trailing twelve months is around 0.74%.


TTM20242023202220212020201920182017201620152014
EW
Edwards Lifesciences Corporation
0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%
LLY
Eli Lilly and Company
0.74%0.67%0.78%1.07%1.23%1.75%1.96%1.95%2.46%2.77%2.37%2.84%

Drawdowns

EW vs. LLY - Drawdown Comparison

The maximum EW drawdown since its inception was -54.32%, smaller than the maximum LLY drawdown of -68.27%. Use the drawdown chart below to compare losses from any high point for EW and LLY. For additional features, visit the drawdowns tool.


Loading data...

Volatility

EW vs. LLY - Volatility Comparison

The current volatility for Edwards Lifesciences Corporation (EW) is 8.41%, while Eli Lilly and Company (LLY) has a volatility of 22.29%. This indicates that EW experiences smaller price fluctuations and is considered to be less risky than LLY based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading data...

Financials

EW vs. LLY - Financials Comparison

This section allows you to compare key financial metrics between Edwards Lifesciences Corporation and Eli Lilly and Company. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


0.002.00B4.00B6.00B8.00B10.00B12.00B14.00B20212022202320242025
1.41B
12.73B
(EW) Total Revenue
(LLY) Total Revenue
Values in USD except per share items

EW vs. LLY - Profitability Comparison

The chart below illustrates the profitability comparison between Edwards Lifesciences Corporation and Eli Lilly and Company over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

Gross Margin
Operating Margin
Net Margin
Quarterly
Annual

72.0%74.0%76.0%78.0%80.0%82.0%20212022202320242025
78.8%
82.5%
(EW) Gross Margin
(LLY) Gross Margin
EW - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on May 2025, Edwards Lifesciences Corporation reported a gross profit of 1.11B and revenue of 1.41B. Therefore, the gross margin over that period was 78.8%.

LLY - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on May 2025, Eli Lilly and Company reported a gross profit of 10.50B and revenue of 12.73B. Therefore, the gross margin over that period was 82.5%.

EW - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on May 2025, Edwards Lifesciences Corporation reported an operating income of 409.90M and revenue of 1.41B, resulting in an operating margin of 29.0%.

LLY - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on May 2025, Eli Lilly and Company reported an operating income of 5.41B and revenue of 12.73B, resulting in an operating margin of 42.5%.

EW - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on May 2025, Edwards Lifesciences Corporation reported a net income of 358.00M and revenue of 1.41B, resulting in a net margin of 25.3%.

LLY - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on May 2025, Eli Lilly and Company reported a net income of 2.76B and revenue of 12.73B, resulting in a net margin of 21.7%.